Initial Clinical Experience with Clinafloxacin in the Treatment of Serious Infections
Miscellaneous Clinical Studies
- 7 Downloads
KeywordsCystic Fibrosis Cystic Fibrosis Patient Bronchiectasis Sparfloxacin Fleroxacin
Unable to display preview. Download preview PDF.
- 1.Fuchs PC, Barry AL, Pfaller MA, et al. Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates. Antimicrob Agents Chemother 1991; 35 (4): 764–6PubMedCrossRefGoogle Scholar
- 2.Jones RN, Johnson DM. Modification for disk diffusion susceptibility testing criteria of CLF (CI-960, AM-1091, CP127371) and fleroxacin (RO 23-6240, AM-833) following studies with a challenge-panel of ciprofloxacin-resistant clinical isolates. Diagn Microbiol Infect Dis. In pressGoogle Scholar
© Adis International Limited 1995